ProCE Banner Activity

ADVANCE IV: Phase III Trial of IV Efgartigimod in Adults With Primary Immune Thrombocytopenia

Slideset Download
Conference Coverage

In patients with primary/chronic ITP, efgartigimod was associated with clinically and statistically significant improvements in platelet counts vs placebo.

Released: December 14, 2022

Expiration: December 13, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen